Vnitr Lek 2009, 55(4):421-424

New and Older Pharmaceuticals Influencing Insulin Secretion

J. Olšovský
Diabetologické centrum II. interní kliniky Lékařské fakulty MU a FN u sv. Anny Brno, přednosta prof. MUDr. Miroslav Souček, CSc.

The author briefly recapitulates the physiology of insulin secretion and pathophysiology with type II diabetes mellitus. Besides sulfonylurea secretagogues and glinides practically used in the long term, the author points out new possibilities of influencing insulin secretion by way of incretin mimetics and gliptins.

Keywords: diabetes mellitus, type II; insulin secretion; sulfonylurea; glinide; incretin mimetic; gliptin

Received: February 2, 2009; Published: April 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Olšovský J. New and Older Pharmaceuticals Influencing Insulin Secretion. Vnitr Lek. 2009;55(4):421-424.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Butler AE, Janson J, Boner-Weir S et al. Mechanism of reduction of betacell. Diabetes 2003; 52: 102-110. Go to original source... Go to PubMed...
    2. www.diab.cz: Standardy: Laboratorní diagnostika a sledování stavu DM.
    3. Perušičová J et al. Perorální antidiabetika. Praha: Galén 2003.
    4. Perušičová J. Léčba perorálními antidiabetiky. Postgrad Med 2003; 5: 726-729.
    5. Rybka J. Současnost a budoucnost perorálních antidiabetik v léčbě diabetu 2. typu. Vnitř Lék 2001; 47: 285-290. Go to PubMed...
    6. Patel A, MacMahon S, Chalmers J et al. The ADVANCE collaboration Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572. Go to original source... Go to PubMed...
    7. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in Type 2 diabetes, a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006; 49: 1711-1721. Go to original source... Go to PubMed...
    8. Olšovský J. Jak používat perorální antidiabetika - algoritmy výběru. Farmakoterapie 2005; 1: 81-85.
    9. Holman RR. Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. Diabetes Res Clin Pract 1998; 40 (Suppl 1): S21-S25. Go to original source... Go to PubMed...
    10. Polonsky KS, Given BD, Hirsch LJ et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. New Engl J Med 1988; 318: 1231-1239. Go to original source... Go to PubMed...
    11. Nauck et al. Diabetologia 1986; 29: 46-52 Go to original source... Go to PubMed...
    12. Larsson H, Holst JJ, Ahrén B. Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol Scand 1997; 160: 413-422. Go to original source... Go to PubMed...
    13. Nauck MA, Wollschläger D, Werner J et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 1996; 39: 1546-1553. Go to original source... Go to PubMed...
    14. Drucker DJ. Glucagon-like peptides. Diabetes 1998; 47: 159-169. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.